TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06691035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: 345 mg (or 86 mg tablets) orally daily during vaccination and continued after until progression.~Cycle Length 28 days (4 weeks)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC1 native/mutated ESR1
Description: 2.0-5.0 x 10 (20-50 million) cells (Injections in groin nodes (or accessible breast tumor if available) weekly with DC1 for eight consecutive weeks, alternating between native ESR1 DC1s and mutated ESR1 DC1s.~Mutated ESR1 DC1s on week 1 followed by native ESR1 DC1s on week 2, alternating during the initial vaccination series and the subsequent booster phase.~Pulsed DC1 will be administered after initial induction every four weeks x 3 doses.
Study: NCT06693648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMZ001 Diclofenac gel
Description: Diclofenac gel applied once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Matching placebo gel applied once daily
Study: NCT06685809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FZ008-145 solution
Description: Dose formulation- Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FZ008-145 Tablet
Description: Dose formulation- Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FZ008-145 Tablet
Description: Dose formulation- Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose formulation- Matching doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose formulation- Matching doses
Study: NCT05842954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLU156
Description: Oral use. KLU156 (400/480 mg) is the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg will take a fraction of the dose according to weight group as defined in the protocol.
Study: NCT04907721

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon
Description: The test consists of two experimental study days:~Day 1: intravenous bolus-injection of glucagon (0.2 mg at time 0 minutes) evaluating the effect of exogenous glucagon on amino acid disappearance. Blood samples will be obtained from time -10 to 120 minutes.~Day 2: 45-minute intravenous infusion of mixed amino acids (331 mg/min/kg body weight from time 0-45 minutes) to evaluate the effect of endogenous glucagon on amino acid metabolism. Blood samples will be obtained from time -10 to 180 minutes.~All participants will be subjected to a magnetic resonance imaging scan to assess whole-liver steatosis, and a bioelectrical impedance analysis to assess body composition.~Following study inclusion and the magnetic resonance imaging scan, participants will be stratified into groups based on hepatic steatosis. Individuals with \<5.6 % hepatic steatosis will be classified as controls and individuals with ≥5.6 % hepatic steatosis will be classified as MASLD.
Study: NCT05463575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketohexokinase inhibition
Description: participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
Study: NCT05592964

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fasting
Description: Standard fasting

Intervention type: DIETARY_SUPPLEMENT
Intervention: Water
Description: In Group S, water was given 1 hour before the operation.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Carbohydrate fluid
Description: In Group K, carbohydrate fluid was given 1 hour before the operation.
Study: NCT06698380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: The subjects of the control group received the CPT based on their routine physical therapy neurological evaluation. The CPT was individualized based on the needs of the subjects. It included: normalization of muscle tone, strengthening of weak muscles, lengthening of tight muscles, training for transfers like supine to sit, sit to stand, balance training, and gait training. The upper extremity training for ADLs also were incorporated using mobilization, reaching, grasping and dexterity movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: A mirror was positioned in front of the subjects to shield the involved upper extremity, reflecting the image of the uninvolved side. The involved upper extremity was placed in a relaxed posture beside the mirror, mirroring the same posture on the uninvolved side to enhance illusional movements. The MT for the experimental group included reaching, grasping, and dexterity movements of the unaffected upper limb, followed by imitation on the involved side. Subjects performed five activities: finger flexion and extension, finger opposition, counting with fingers, wrist flexion and extension, and forearm supination and pronation. Each activity was done 10 times, with mirror therapy lasting 15 minutes followed by 30 minutes of CPT treatment. Each session lasted 45 minutes, held three times per week over six weeks.
Study: NCT06699251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chat
Description: Chat is a brief motivational interviewing intervention for partner clinic participants with an alcohol or cannabis use condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: An informational brochure will be give to partner clinic participants with an alcohol or cannabis use condition.
Study: NCT06699472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Vincristine (V), intravenous injection, 1.5 mg/m2 (maximum not exceeding 2mg), D1, odd cycle administration Doxorubicin (D), intravenous infusion, 75mg/m2, D1, odd cycle administration When the cumulative dose of doxorubicin is ≥ 375mg/m2, replace it with actinomycin D 1.25mg/m2 Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration Etoposide (E), intravenous infusion, 100mg/m2, D1-5, even cycle administration
Study: NCT05842954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Oral use. Dosing will be selected based on patient's body weight as per product's label.
Study: NCT05031078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap.
Study: NCT06699472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Vincristine (V), intravenous injection, 1.5 mg/m2 (maximum not exceeding 2mg), D1, odd cycle administration Doxorubicin (D), intravenous infusion, 75mg/m2, D1, odd cycle administration When the cumulative dose of doxorubicin is ≥ 375mg/m2, replace it with actinomycin D 1.25mg/m2 Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration Etoposide (E), intravenous infusion, 100mg/m2, D1-5, even cycle administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib Injection [Cosela]
Description: Trilaciclib, intravenous infusion, 240 mg/m2, administered following chemotherapy (2 hours after completion of vincristine administration and within 4 hours before administration of other chemotherapy drugs)
Study: NCT06699862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Throughout the 10-weeks intervention period, B2L-M HIIT sessions will be delivered during regular PE classes twice a week, by the schools' PE teachers. The HIIT sessions will be applied in the first 8-10 min of each PE class, including a brief warm-up involving a combination of aerobic and body weight muscle-strengthening exercises, and designed to be fun and engaging as well as vigorous in nature

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training with Competition
Description: Students will participate in a school competition to win points for their class for a 10-week period. In every HIIT session the heart rate will be tracked to measure the exercise intensity and also it will be used to win points for the competition. Every class will receive the same number of points as the sum of the minutes of exercise at a vigorous intensity (i.e., ≥85% max. heart rate) of each participant. This fact means that the physical fitness is irrelevant to the competition aspect, which will only consider the effort of the participants.
Study: NCT06699394

Intervention type: DRUG
Group type: OTHER
Intervention: Teclistamab (Tec)
Description: Teclistamab is administered subcutaneously with the usual step-up dosing: 0.06 mg/kg at day 1, 0.3 mg/kg at day 4, 1.5 mg/kg at day 8, and then 1.5 mg/kg weekly.
Study: NCT06699524

Intervention type: DRUG
Intervention: in vitro （chemotherapy）
Description: resuscitating PDTO from the organoid biobank, patients were categorized into drug-sensitive and drug-resistant groups based on the optimal cutoff value for PDTO drug testing. We then followed up to analyze the correlation between PDTO drug testing and RFS.

Intervention type: DRUG
Intervention: in vitro （chemotherapy）
Description: resuscitating PDTO from the organoid biobank, patients were categorized into drug-sensitive and drug-resistant groups based on the optimal cutoff value for PDTO drug testing. We then followed up to analyze the correlation between PDTO drug testing and RFS.

Intervention type: DEVICE
Intervention: Adjuvant TACE（Adjuvant Transarterial Chemoembolization）
Description: Adjuvant TACE was performed 4 to 8 weeks postoperatively, with a chemotherapy regimen of 50 mg of doxorubicin and 50 mg of oxaliplatin.

Intervention type: DEVICE
Intervention: Adjuvant TACE（Adjuvant Transarterial Chemoembolization）
Description: Adjuvant TACE was performed 4 to 8 weeks postoperatively, with a chemotherapy regimen of 50 mg of doxorubicin and 50 mg of oxaliplatin.
Study: NCT06699563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilization Motivation Card
Description: On the morning of the surgery, the Mobilization Motivation Card and Pedometer will be introduced and the patient will be informed. On the morning of the first postoperative day, before the patient's first mobilization, pain assessment will be made with the Visual Analog Scale (VAS), and the Mobilization Motivation Card will be hung at the bedside during the day and will help increase the patient's participation in mobilization. Later, after a pedometer is attached to the patient's waist, the patient will be mobilized.
Study: NCT06699186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep
Description: A training programme was devised which involved the participants performing maximum squat repetitions with their own body weight as a workload, in order to induce delayed-onset muscle soreness in the quadriceps. Before the maximum squat repetition, all participants performed a warm-up programme including 5 minutes of walking. Participants were instructed to perform the maximum number of repetitions within the one minute allotted for each set of squats and, after a 10-second rest period, to continue the programme in the same cycle until exhaustion. In the initial 24-hour period following the intervention, participants were instructed to maintain their habitual sleep schedules. In consideration of the delayed-onset muscle soreness, which typically occurs between 24 to 48 hours following maximal squat intervention.The sleep group was instructed to engage in a minimum of six hours of sleep over the course of the 24-hour observation period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-sleep
Description: A similar delayed-onset muscle soreness inducing protocol was applied to the sleep group.Participants in the non-sleep group were subjected to sleep restriction. The participants were permitted to sleep for a maximum of four hours in total over the course of the 24-hour period in non-sleep group.
Study: NCT06699017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous anterior chest compression
Description: CACC is performed manually and the pressure applied will be maintained between 60 and 80 cmH2O.
Study: NCT06698679

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study. We will obtain blood from the recruited patients and assess the metabolites therein. This is an observational work.

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study. We will obtain blood from the recruited patients and assess the metabolites therein. This is an observational work.

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study. We will obtain blood from the recruited patients and assess the metabolites therein. This is an observational work.
Study: NCT06699043

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nanocrystalline hydroxyapatite in putty form
Description: decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space.~* Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa~* The intrabony defects in Group I will be received nanocrystalline hydroxyapatite in putty form as grafting material (NanoBone® SBX Putty).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized Bone Matrix allograft putty
Description: decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space. • Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa • The intrabony defects in Group II will be received Demineralized Bone Matrix allograft putty as grafting material, in both groups will be use membrane to cover of the graft materials and finally will be sutured the flap.
Study: NCT06700304

Intervention type: DEVICE
Group type: OTHER
Intervention: N1 Implant
Description: The N1 Implant is a type of implantable brain-computer interface.

Intervention type: DEVICE
Group type: OTHER
Intervention: R1 Robot
Description: The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
Study: NCT06698991

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: • Plasma exchange (1.5 times plasma exchange)~* Blood volume: 80ml/kg~* Plasma volume = Blood volume x (1 - Hematocrit/100)~* TPE volume = 1.5 x plasma volume~* Duration: 4 hours
Study: NCT05673278

Intervention type: DIAGNOSTIC_TEST
Intervention: Bowel Ultrasound Scan
Description: Ultrasound scans will attempt to measure predefined criteria implemented in other research work using bowel ultrasound.~I - Bowel wall thickness II - Colour Doppler signal III - Loss of wall layer stratification IV - Loss of haustration V - Fatty wrapping VI - Motility in terminal ileum (TI) VII - Lymphadenopathy VIII - Abscess IX - Stricture~+ Image quality
Study: NCT06226753

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type of anaesthesia used
Description: Spinal anaesthesia will be used for closure of loop ileostomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of anaesthesia used
Description: Spinal anaesthesia will be used for closure of loop ileostomy
Study: NCT05654753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active FMT
Description: MaaT033®, a lyophilized full-ecosystem intestinal microbiota delayed release oral capsule containing native, donor-derived (pooled from 4-6 donors) microbiome product manufactured by MaaT Pharma® will be delivered orally. Patients will receive 20 Maat033 capsules, each containing approximatively 0.42 g of microbiome product at once at day 0, then 3 capsules/day from day 1 through day 20.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 20 capsules placebo, each containing placebo at once at day 0, then 3 capsules/day from day 1 through day 20.
Study: NCT05031078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine injections
Description: 1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 1-2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg.
Study: NCT06698991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: • Plasma exchange (1.5 times plasma exchange)~* Blood volume: 80ml/kg~* Plasma volume = Blood volume x (1 - Hematocrit/100)~* TPE volume = 1.5 x plasma volume~* Duration: 4 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study: NCT06699069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control or Euthyroid group
Description: Fed on normal standard diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothyroid group
Description: Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothyroid group received exercise
Description: Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise. The exercise groups will be adapted to a round water tank (70 cm × 70 cm) containing water at 28 ± 2°C for 3 days (10-45 min/day). The rats will then begin swimming, 45 min/day for the first two weeks at 10am and 60 min/day for the last six weeks at 10am
Study: NCT04274530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.
Study: NCT05570617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Coach Intervention
Description: The Transition Coach Intervention will include 8, 1-hour sessions over 6-months. The transition coach will independently meet one-on-one with each youth using an individualized, patient-centred approach beginning with an introductory session, followed by 5 sessions covering each topic in the Youth Transition Roadmap. These topics include: Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. The clinical psychologist will lead 2 sessions beginning with the Patient Health Questionnaire for Anxiety and Depression as a screening tool. The clinical psychologist will discuss psychological and social well-being in the context of their disease covering personally relevant issues/concerns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care- Youth Transition Roadmap
Description: All participants will receive the Youth Transition Roadmap (standard of care) which discusses 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. This is an informational pamphlet and will not require any additional meetings with the patient beyond their normal healthcare interactions
Study: NCT05031078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine injections
Description: 1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 1-2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine injections
Description: 1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 1-2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg.
Study: NCT04719754

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal swab
Description: The other vaginal swab will be cultured on blood agar, chocolate agar, MacConkey agar and Sabourauds dextrose agar. The cultures will be incubated at 37ºC for 24-96 h or until the colonies appear.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal swab
Description: The other vaginal swab will be cultured on blood agar, chocolate agar, MacConkey agar and Sabourauds dextrose agar. The cultures will be incubated at 37ºC for 24-96 h or until the colonies appear.
Study: NCT05721937

Intervention type: DRUG
Intervention: Abrocitinib
Description: taken by mouth